FDA Tightens SaMD Entry Rules for U.S. Market: learn how new FDA SaMD guidance on data security and clinical validation could impact exports, compliance timelines, and launch readiness.

FDA Tightens SaMD Rules for Edge AI Validation: learn how the 2026 update affects 510(k), De Novo, latency thresholds, offline accuracy, and compliance costs for AI diagnostic software.

FDA Tightens SaMD Path for AI Diagnostic Software: learn how the new FDA SaMD real-world data validation rule may delay U.S. filings, reshape clinical partnerships, and impact Chinese exporters.

FDA Tightens SaMD Path for AI Diagnostic Software: learn how new FDA algorithm traceability rules may delay 510(k) and De Novo submissions, raise compliance workload, and impact U.S. export planning.